Novel plant microRNAs from broccoletti sprouts do not show cross-kingdom regulation of pancreatic cancer
Novel plant microRNAs from broccoletti sprouts do not show cross-kingdom regulation of pancreatic cancer |
|
https://doi.org/10.18632/oncotarget.27527
Xi Xiao,
Carsten Sticht,
Libo Yin,
Li Liu,
Svetlana Karakhanova,
Yefeng Yin,
Christina Georgikou,
Jury Gladkich,
Wolfgang Gross,
Norbert Gretz,
and Ingrid Herr
|
| 1203-1217 |
A phase II randomized clinical trial using aglycone isoflavones to treat patients with localized prostate cancer in the pre-surgical period prior to radical prostatectomy
A phase II randomized clinical trial using aglycone isoflavones to treat patients with localized prostate cancer in the pre-surgical period prior to radical prostatectomy |
|
https://doi.org/10.18632/oncotarget.27529
Nagi B. Kumar,
Julio Pow-Sang,
Philippe Spiess,
Shohreh Dickinson,
and Michael J. Schell
|
| 1218-1234 |
A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies
A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies |
|
https://doi.org/10.18632/oncotarget.27530
Matthew H. Taylor,
Ajjai S. Alva,
Timothy Larson,
Sebastian Szpakowski,
Das Purkaystha,
Alpesh Amin,
Linda Karpiak,
and Sarina A. Piha-Paul
|
| 1235-1243 |
Does breast carcinoma belong to the Lynch syndrome tumor spectrum? – Somatic mutational profiles vs. ovarian and colorectal carcinomas
Does breast carcinoma belong to the Lynch syndrome tumor spectrum? – Somatic mutational profiles vs. ovarian and colorectal carcinomas |
|
https://doi.org/10.18632/oncotarget.27538
Noora K. Porkka,
Alisa Olkinuora,
Teijo Kuopio,
Maarit Ahtiainen,
Samuli Eldfors,
Henrikki Almusa,
Jukka-Pekka Mecklin,
and Päivi Peltomäki
|
| 1244-1256 |
Inhibition of SYK kinase does not confer a pro-proliferative or pro-invasive phenotype in breast epithelium or breast cancer cells
Inhibition of SYK kinase does not confer a pro-proliferative or pro-invasive phenotype in breast epithelium or breast cancer cells |
|
https://doi.org/10.18632/oncotarget.27545
David J. Lamb,
Aleksander Rust,
Albin Rudisch,
Tobias Glüxam,
Nathalie Harrer,
Herwig Machat,
Ingrid Christ,
Florian Colbatzky,
Andreas Wernitznig,
Annika Osswald,
and Wolfgang Sommergruber
|
| 1257-1272 |
First-in-human study of anticancer immunotherapy drug candidate mobilan: safety, pharmacokinetics and pharmacodynamics in prostate cancer patients
First-in-human study of anticancer immunotherapy drug candidate mobilan: safety, pharmacokinetics and pharmacodynamics in prostate cancer patients |
|
https://doi.org/10.18632/oncotarget.27549
Natalia V. Eremina,
Vasily I. Kazey,
Sergey V. Mishugin,
Roman V. Leonenkov,
Dmitry Y. Pushkar,
Vadim L. Mett,
and Andrei V. Gudkov
|
| 1273-1288 |
Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models
Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models |
|
https://doi.org/10.18632/oncotarget.27407
Sunkyu Kim,
Ralph Tiedt,
Alice Loo,
Thomas Horn,
Scott Delach,
Steven Kovats,
Kristy Haas,
Barbara Schacher Engstler,
Alexander Cao,
Maria Pinzon-Ortiz,
Iain Mulford,
Michael G. Acker,
Rajiv Chopra,
Christopher Brain,
Emmanuelle di Tomaso,
William R. Sellers,
and Giordano Caponigro
|
| 1289-1289 |
Correction: Exclusive destruction of mitotic spindles in human cancer cells
Correction: Exclusive destruction of mitotic spindles in human cancer cells |
|
https://doi.org/10.18632/oncotarget.27499
Leonid Visochek,
Asher Castiel,
Leonid Mittelman,
Michael Elkin,
Dikla Atias,
Talia Golan,
Shai Izraeli,
Tamar Peretz,
and Malka Cohen-Armon
|
| 1290-1291 |
